![Allakos Inc](/common/images/company/N_ALLK.png)
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Sig... Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.025 | 9.08430232558 | 0.2752 | 0.3127 | 0.2554 | 1765544 | 0.27910029 | CS |
4 | -0.6978 | -69.9198396794 | 0.998 | 1.26 | 0.23 | 5893851 | 0.28948565 | CS |
12 | -0.5661 | -65.3468775251 | 0.8663 | 1.38 | 0.23 | 2295924 | 0.39846196 | CS |
26 | -0.3822 | -56.0082063306 | 0.6824 | 1.555 | 0.23 | 1352209 | 0.56532906 | CS |
52 | -0.9898 | -76.7286821705 | 1.29 | 1.69 | 0.23 | 970491 | 0.74452294 | CS |
156 | -6.1098 | -95.3166926677 | 6.41 | 8.73 | 0.23 | 1169225 | 3.37959975 | CS |
260 | -69.7498 | -99.571448965 | 70.05 | 157.98 | 0.23 | 1020194 | 13.43618736 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관